CA2527321A1 - Gene expression markers for response to egfr inhibitor drugs - Google Patents

Gene expression markers for response to egfr inhibitor drugs Download PDF

Info

Publication number
CA2527321A1
CA2527321A1 CA002527321A CA2527321A CA2527321A1 CA 2527321 A1 CA2527321 A1 CA 2527321A1 CA 002527321 A CA002527321 A CA 002527321A CA 2527321 A CA2527321 A CA 2527321A CA 2527321 A1 CA2527321 A1 CA 2527321A1
Authority
CA
Canada
Prior art keywords
dna
artificial sequence
expression
cancer
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002527321A
Other languages
English (en)
French (fr)
Inventor
David Agus
Joffre B. Baker
Ronald Natale
Steven Shak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars-Sinai Medical Center
Genomic Health Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2527321A1 publication Critical patent/CA2527321A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA002527321A 2003-05-30 2004-05-28 Gene expression markers for response to egfr inhibitor drugs Abandoned CA2527321A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47490803P 2003-05-30 2003-05-30
US60/474,908 2003-05-30
PCT/US2004/017215 WO2004111273A2 (en) 2003-05-30 2004-05-28 Gene expression markers for response to egfr inhibitor drugs

Publications (1)

Publication Number Publication Date
CA2527321A1 true CA2527321A1 (en) 2004-12-23

Family

ID=33551513

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002527321A Abandoned CA2527321A1 (en) 2003-05-30 2004-05-28 Gene expression markers for response to egfr inhibitor drugs

Country Status (6)

Country Link
US (2) US20050164218A1 (enExample)
EP (2) EP2226396A1 (enExample)
JP (1) JP2007506442A (enExample)
AU (2) AU2004248140A1 (enExample)
CA (1) CA2527321A1 (enExample)
WO (1) WO2004111273A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059012A1 (en) * 2002-07-31 2005-03-17 Daniel Afar Diagnosis of ZD1839 resistant tumors
US20050267689A1 (en) * 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc OXYGEN-IMPROVED MEMBRANE SYSTEMS FOR IMPLANTABLE DEVICES
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
JP5422120B2 (ja) 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2006101925A2 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US7635570B2 (en) 2005-04-01 2009-12-22 Salvatore Siena Epidermal growth factor receptor gene copy number
CA2604844A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
AU2006233675A1 (en) * 2005-04-14 2006-10-19 Merck Patent Gmbh Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
JP2008541701A (ja) * 2005-05-04 2008-11-27 ユニヴァーシティ オブ サウス フロリダ がんの対象における処置応答の予測
SI1913157T2 (sl) * 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
ES2354181T3 (es) * 2006-02-16 2011-03-10 Ventana Medical Systems, Inc. Reactivos y métodos para el pronóstico y estadificación patológica del cáncer.
US20070207467A1 (en) * 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
JP2007252312A (ja) * 2006-03-24 2007-10-04 Japan Health Science Foundation 上皮成長因子受容体−チロシンキナーゼ阻害剤に対する肺ガンの感度測定方法および肺ガン治療剤のスクリーニング方法
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US8024282B2 (en) * 2006-03-31 2011-09-20 Biodesix, Inc. Method for reliable classification of samples in clinical diagnostics using an improved method of classification
US7858390B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7858389B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US20070281305A1 (en) * 2006-06-05 2007-12-06 Sean Wuxiong Cao Detection of lymph node metastasis from gastric carcinoma
EP2061906B1 (en) * 2006-09-12 2011-08-31 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
US20080293055A1 (en) 2007-03-13 2008-11-27 Daniel Freeman K-ras mutations and anti-EGFr antibody therapy
US8377636B2 (en) 2007-04-13 2013-02-19 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to kinase inhibitors
WO2009023172A2 (en) * 2007-08-09 2009-02-19 The Johns Hopkins University Predictions of responsiveness to egfr inhibitors
WO2009021679A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treamtent
WO2009021682A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
KR20100044851A (ko) * 2007-08-14 2010-04-30 에프. 호프만-라 로슈 아게 Ｅｇｆｒ 억제제를 이용한 치료에 대한 예측 마커
AU2008286337B2 (en) 2007-08-14 2011-10-27 F. Hoffmann-La Roche Ag Predictive marker for EGFR inhibitor treatment
CA2695070A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
MX2010001578A (es) * 2007-08-14 2010-03-15 Hoffmann La Roche Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
AU2008307634A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
NZ589143A (en) * 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
WO2010015536A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
WO2010015538A2 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
WO2010015535A1 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
EP3075864A1 (en) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
EP2722400A3 (en) * 2008-10-29 2014-07-09 William Beaumont Hospital Methods of using biomarkers
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
WO2010064702A1 (ja) * 2008-12-05 2010-06-10 国立大学法人 東京大学 癌の予後を予測するためのバイオマーカー
US20110171124A1 (en) * 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
KR101556726B1 (ko) * 2010-02-24 2015-10-02 바이오디식스, 인크. 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
SG2014011316A (en) 2011-08-31 2014-06-27 Genentech Inc Diagnostic markers
JP2014531213A (ja) 2011-09-30 2014-11-27 ジェネンテック， インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
CA2862739A1 (en) * 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
CN103408662A (zh) * 2013-08-15 2013-11-27 浙江农林大学 一种抗蟾皮转胶蛋白-2重组蛋白的鼠抗血清的制备方法
WO2015178946A1 (en) 2014-04-04 2015-11-26 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
WO2016018087A1 (ko) * 2014-07-29 2016-02-04 재단법인 아산사회복지재단 Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
KR102406696B1 (ko) * 2020-06-19 2022-06-08 (주)신테카바이오 약물 민감도 판단을 위한 유전자 검출 방법 및 진단용 조성물
JPWO2022255401A1 (enExample) * 2021-06-03 2022-12-08

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) * 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
JP3944241B2 (ja) * 1995-12-18 2007-07-11 スージェン・インコーポレーテッド Ａｕｒ―１および／またはａｕｒ―２関連疾患の診断および処置
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) * 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6203993B1 (en) * 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6143529A (en) * 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5861278A (en) * 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) * 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6919178B2 (en) * 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6998233B2 (en) * 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
US9534254B1 (en) * 1999-02-02 2017-01-03 Abbott Molecular Inc. Patient stratification for cancer therapy based on genomic DNA microarray analysis
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) * 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
EP1276901A2 (en) * 2000-01-13 2003-01-22 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) * 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US6618679B2 (en) * 2000-01-28 2003-09-09 Althea Technologies, Inc. Methods for analysis of gene expression
US7157227B2 (en) * 2000-03-31 2007-01-02 University Of Louisville Research Foundation Microarrays to screen regulatory genes
AU2001264559A1 (en) * 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2001280008A1 (en) * 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
JP4368110B2 (ja) * 2001-01-12 2009-11-18 エール ユニヴァーシティ 癌患者の生物学的流体中のサバイビンの検出
US7776518B2 (en) * 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
KR20030094281A (ko) * 2001-03-12 2003-12-11 모노젠, 인크. 세포에 기초한 질병상태의 검출 및 질병상태의 구별
AU2002343443A1 (en) * 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
EP1470247A2 (en) * 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
CN1612936A (zh) * 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US8008003B2 (en) * 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer

Also Published As

Publication number Publication date
JP2007506442A (ja) 2007-03-22
US20050164218A1 (en) 2005-07-28
US20080318230A1 (en) 2008-12-25
AU2004248140A1 (en) 2004-12-23
EP1636380A2 (en) 2006-03-22
AU2009248449A1 (en) 2010-01-07
WO2004111273A2 (en) 2004-12-23
EP2226396A1 (en) 2010-09-08
WO2004111273A3 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
AU2004211955B2 (en) Gene expression markers for response to EGFR inhibitor drugs
US20050164218A1 (en) Gene expression markers for response to EGFR inhibitor drugs
US8148076B2 (en) Gene expression profiling of EGFR positive cancer
AU2004248120B2 (en) Gene expression markers for predicting response to chemotherapy
US7723033B2 (en) Prediction of likelihood of cancer recurrence
CA2563074C (en) Gene expression markers for predicting response to chemotherapy
JP2006521793A5 (enExample)
JP2006506093A5 (enExample)
JP2013532482A (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
US20120004127A1 (en) Gene expression markers for colorectal cancer prognosis
AU2017228579B2 (en) Prediction of likelihood of cancer recurrence
HK1148320A (en) Gene expression markers for response to egfr inhibitor drugs
HK1201569B (en) Prediction of likelihood of cancer recurrence

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued